Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
HEIDELBERG, Germany, May 31, 2016 -- Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the Jefferies 2016 Healthcare Conference on Tuesday, June 7, 2016 at 8:30 a.m. (ET) in New York City.
To access a simultaneous webcast of Dr. Hoess' presentation online, log on to http://wsw.com/webcast/jeff97/afmd or go to the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available from Affimed's website for 30 days following the conference. Dr. Hoess' presentation will be available for download in PDF format immediately following the conference presentation in the "Events" section of the Media page of Affimed's website at http://www.affimed.com/events.php.
About Affimed N.V.
Affimed (Nasdaq:AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
CONTACT: IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications
Phone: +49 6221 64793341
E-Mail: [email protected]
